Literature DB >> 7516270

Molecular basis for antibody cross-reactivity between the hepatitis C virus core protein and the host-derived GOR protein.

Z X Zhang1, M Chen, K Wallhagen, J Trojnar, L O Magnius, B Wahren, M Sällberg.   

Abstract

The presence of antibodies reactive to a recently cloned host-derived antigen GOR is highly correlated with the presence of antibodies to the hepatitis C virus (HCV). We explored the molecular basis for this observation, and address the following question: are antibodies reactive with GOR19-27 (QKAKSNPNR) a result of a cross-reactivity triggered by the antigenic region at residues 9-17 of HCV core (RKTKRNTNR)? We compared the relative antibody avidity between antibodies reactive to both regions, and determined the residues essential for antibody binding using substitution peptide analogues. Of 96 sera assayed, 60 were found positive for anti-HCV, and of these 55 were found to react with HCV core. Twenty-nine sera were found reactive to the GOR peptide, and these were all reactive to HCV core. In most cases the relative antibody avidity of antibodies reactive to GOR was higher for the HCV core peptide. In 21 of the GOR-reactive sera we were able to determine the essential residues for antibody binding. The essential residues in > 50% of all tested sera coincided with the well conserved residues Lys10, Lys12, Asn14, and Asn16. Also, reactivity to GOR was not related to any certain serotype of antibodies to HCV. Taken together, these findings explain at the molecular level the observed cross-reactivity between these two proteins, since sequence homology per se is not evidence for cross-reactivity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7516270      PMCID: PMC1534578          DOI: 10.1111/j.1365-2249.1994.tb06042.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  23 in total

1.  Nucleotide sequence of core and envelope genes of the hepatitis C virus genome derived directly from human healthy carriers.

Authors:  K Takeuchi; Y Kubo; S Boonmar; Y Watanabe; T Katayama; Q L Choo; G Kuo; M Houghton; I Saito; T Miyamura
Journal:  Nucleic Acids Res       Date:  1990-08-11       Impact factor: 16.971

2.  [A non-A non-B hepatitis specific epitope GOR and its antibodies].

Authors:  S Mishiro
Journal:  Nihon Rinsho       Date:  1991-02

3.  An autoantibody cross-reactive to hepatitis C virus core and a host nuclear antigen.

Authors:  S Mishiro; K Takeda; Y Hoshi; A Yoshikawa; T Gotanda; Y Itoh
Journal:  Autoimmunity       Date:  1991       Impact factor: 2.815

4.  Rapid "tea-bag" peptide synthesis using 9-fluorenylmethoxycarbonyl (Fmoc) protected amino acids applied for antigenic mapping of viral proteins.

Authors:  M Sällberg; U Rudén; L O Magnius; E Norrby; B Wahren
Journal:  Immunol Lett       Date:  1991-09       Impact factor: 3.685

5.  Hepatitis C viral cDNA clones isolated from a healthy carrier donor implicated in post-transfusion non-A, non-B hepatitis.

Authors:  K Takeuchi; S Boonmar; Y Kubo; T Katayama; H Harada; A Ohbayashi; Q L Choo; G Kuo; M Houghton; I Saito
Journal:  Gene       Date:  1990-07-16       Impact factor: 3.688

6.  The 5'-terminal sequence of the hepatitis C virus genome.

Authors:  H Okamoto; S Okada; Y Sugiyama; S Yotsumoto; T Tanaka; H Yoshizawa; F Tsuda; Y Miyakawa; M Mayumi
Journal:  Jpn J Exp Med       Date:  1990-06

7.  Non-A, non-B hepatitis specific antibodies directed at host-derived epitope: implication for an autoimmune process.

Authors:  S Mishiro; Y Hoshi; K Takeda; A Yoshikawa; T Gotanda; K Takahashi; Y Akahane; H Yoshizawa; H Okamoto; F Tsuda
Journal:  Lancet       Date:  1990-12-08       Impact factor: 79.321

8.  Mapping of serotype-specific, immunodominant epitopes in the NS-4 region of hepatitis C virus (HCV): use of type-specific peptides to serologically differentiate infections with HCV types 1, 2, and 3.

Authors:  P Simmonds; K A Rose; S Graham; S W Chan; F McOmish; B C Dow; E A Follett; P L Yap; H Marsden
Journal:  J Clin Microbiol       Date:  1993-06       Impact factor: 5.948

9.  High-affinity antibody induced by immunization with a synthetic peptide is associated with protection of cattle against foot-and-mouth disease.

Authors:  M W Steward; C M Stanley; R Dimarchi; G Mulcahy; T R Doel
Journal:  Immunology       Date:  1991-01       Impact factor: 7.397

10.  Anti-GOR and hepatitis C virus in autoimmune liver diseases.

Authors:  G Michel; A Ritter; G Gerken; K H Meyer zum Büschenfelde; R Decker; M P Manns
Journal:  Lancet       Date:  1992-02-01       Impact factor: 79.321

View more
  9 in total

1.  Characterization of the recognition site and diagnostic potential of an enterovirus group-reactive monoclonal antibody.

Authors:  A Samuelson; M Forsgren; M Sällberg
Journal:  Clin Diagn Lab Immunol       Date:  1995-05

2.  Immunoblot analysis of CD34 expression in histologically diverse neoplasms.

Authors:  Y Natkunam; R V Rouse; S Zhu; C Fisher; M van De Rijn
Journal:  Am J Pathol       Date:  2000-01       Impact factor: 4.307

3.  The GOR gene product cannot cross-react with hepatitis C virus in humans.

Authors:  R Koike; T Iizuka; T Watanabe; N Miyasaka
Journal:  Clin Exp Immunol       Date:  2001-06       Impact factor: 4.330

Review 4.  The humoral immune response in acute and chronic hepatitis B virus infection.

Authors:  D R Milich; M Sallberg; T Maruyama
Journal:  Springer Semin Immunopathol       Date:  1995

5.  Antibody production against hepatitis C virus core and nonstructural 3 proteins is highly sensitive to deficits in T-cell function.

Authors:  Y Ando; A Sönnerborg; L Barkholt; A Birkett; B G Ericzon; M Sällberg
Journal:  Clin Diagn Lab Immunol       Date:  1997-01

Review 6.  Hepatitis C: progress and problems.

Authors:  J A Cuthbert
Journal:  Clin Microbiol Rev       Date:  1994-10       Impact factor: 26.132

7.  Serum immunoglobulin G antibodies to the GOR autoepitope are present in patients with occult hepatitis C virus (HCV) infection despite lack of HCV-specific antibodies.

Authors:  Juan A Quiroga; Inmaculada Castillo; Javier Bartolomé; Vicente Carreño
Journal:  Clin Vaccine Immunol       Date:  2007-08-15

8.  Antigenic structure of the hepatitis C virus envelope 2 protein.

Authors:  Z X Zhang; A Sönnerborg; M Sällberg
Journal:  Clin Exp Immunol       Date:  1994-12       Impact factor: 4.330

9.  Hepatitis C virus, human immunodeficiency virus and Pseudomonas phage PS5 triad share epitopes of immunogenic determinants.

Authors:  Zhabiz Golkar; Nusrat Jamil
Journal:  Virol J       Date:  2010-11-26       Impact factor: 4.099

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.